Literature DB >> 19619670

Call for a reference model of chronic hind limb ischemia to investigate therapeutic angiogenesis.

Zijiang Yang1, Moritz Wyler von Ballmoos, Nicolas Diehm, Iris Baumgartner, Christoph Kalka, Stefano Di Santo.   

Abstract

A large number of studies utilize animal models to investigate therapeutic angiogenesis. However, the lack of a standardized experimental model leaves the comparison of different studies problematic. To establish a reference model of prolonged moderate tissue ischemia, we created unilateral hind limb ischemia in athymic rnu-rats by surgical excision of the femoral vessels. Blood flow of the limb was monitored for 60 days by laser Doppler imaging. Following a short postoperative period of substantially depressed perfusion, the animals showed a status of moderate hind limb ischemia from day 14 onwards. Thereafter, the perfusion remained at a constant level (55.5% of normal value) until the end of the observation period. Histopathological assessment of the ischemic musculature on postoperative days 28 and 60 showed essentially no inflammatory cell infiltrate or fibrosis. However, the mitochondrial activity and capillary-to-fiber ratio of the muscular tissue was reduced to 52.7% of normal, presenting with a significant weakness of the ischemic limb evidenced by a progressive decline in performance. Intramuscular injection of culture-expanded human endothelial progenitor cells (EPC) resulted in a significant increase in blood flow (82.0+/-3.5% of normal), capillary density (1.60+/-0.08/muscle fiber) and smooth muscle covered arterioles (8.0+/-0.6/high power field) in the ischemic hind limb as compared to controls (55.0+/-3.1%; 0.99+/-0.03; 5.0+/-0.2). In conclusion, chronic, moderate hind limb ischemia with consistently reduced perfusion levels persisting over a prolonged period can be established reliably in rnu athymic nude rats and is responsive to pro-angiogenic treatments such as EPC transplantation. This study provides a detailed protocol of a highly reproducible reference model to test novel therapeutic options for limb ischemia.

Entities:  

Mesh:

Year:  2009        PMID: 19619670     DOI: 10.1016/j.vph.2009.07.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  5 in total

1.  Tumor necrosis factor inhibition increases the revascularization of ischemic hind-limbs in diabetic mice.

Authors:  Adel M A Assiri; Hatim A El-Baz; Ali H Amin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-05-31       Impact factor: 3.000

2.  Therapeutic assessment of mesenchymal stem cells delivered within a PEGylated fibrin gel following an ischemic injury.

Authors:  Laura M Ricles; Pei-Ling Hsieh; Nicholas Dana; Viktoriya Rybalko; Chelsea Kraynak; Roger P Farrar; Laura J Suggs
Journal:  Biomaterials       Date:  2016-06-07       Impact factor: 12.479

3.  Endothelial progenitor cells induce a phenotype shift in differentiated endothelial cells towards PDGF/PDGFRβ axis-mediated angiogenesis.

Authors:  Moritz Wyler von Ballmoos; Zijiang Yang; Jan Völzmann; Iris Baumgartner; Christoph Kalka; Stefano Di Santo
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

4.  Improving the therapeutic efficacy of mesenchymal stromal cells to restore perfusion in critical limb ischemia through pulsed focused ultrasound.

Authors:  Pamela A Tebebi; Saejeong J Kim; Rashida A Williams; Blerta Milo; Victor Frenkel; Scott R Burks; Joseph A Frank
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

5.  Inhibition of Prostaglandin Transporter (PGT) Promotes Perfusion and Vascularization and Accelerates Wound Healing in Non-Diabetic and Diabetic Rats.

Authors:  Zhongbo Liu; Outhiriaradjou Benard; Mahrukh M Syeda; Victor L Schuster; Yuling Chi
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.